Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Psychedelic Microdosing: Prevalence and Subjective Effects

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic compounds on a chronic, intermittent schedule—a practice known as psychedelic microdosing—is becoming increasingly popular among young adults due to its purported ability to reduce symptoms of depression and anxiety while improving cognitive function and promoting social interaction. Using an anonymous online survey, we collected data from 2347 people to 1) assess the prevalence of psychedelic microdosing and characterize the demographics of microdosers, 2) determine whether microdosers associate the practice with changes in mood, cognitive function, social interaction, or physiology, and 3) investigate frequent motives for discontinuing the practice. Fifty-nine percent of respondents (N T = 2183) reported familiarity with the concept of psychedelic microdosing, with 17% (383 respondents, N T =2200) having engaged in this practice. Microdosers attributed psychedelic microdosing with improving their mood, decreasing their anxiety, and enhancing their memory, attention, and sociability. The most frequently cited reasons for quitting microdosing (N T = 243) were the risks associated with taking an illegal substance (24.28%) and the difficulty of obtaining psychedelic compounds (22.63%). Overall, our findings suggest that psychedelic microdosing is relatively common and is subjectively associated with a broad spectrum of socio-affective, cognitive, and physical outcomes.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010

          The Lancet, 382(9904), 1575-1586
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

            This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

              Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up. Instructions to participants and staff minimized expectancy effects. Participants, staff, and community observers rated participant moods, attitudes, and behaviors throughout the study. High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with >80% endorsing moderately or greater increased well-being/life satisfaction. Community observer ratings showed corresponding changes. Mystical-type psilocybin experience on session day mediated the effect of psilocybin dose on therapeutic outcomes. Trial Registration ClinicalTrials.gov identifier: NCT00465595
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Journal of Psychoactive Drugs
                Journal of Psychoactive Drugs
                Informa UK Limited
                0279-1072
                2159-9777
                March 14 2020
                January 23 2020
                March 14 2020
                : 52
                : 2
                : 113-122
                Affiliations
                [1 ]Neuroscience Graduate Program, University of California, Davis , Davis, CA, USA
                [2 ]Department of Psychology, University of California, Davis , Davis, CA, USA
                [3 ]Department of Chemistry, University of California, Davis , Davis, CA, USA
                [4 ]Department of Biochemistry & Molecular Medicine, School of Medicine, University of California, Davis , Sacramento, CA, USA
                [5 ]Center for Neuroscience, University of California, Davis , Davis, CA, USA
                Article
                10.1080/02791072.2020.1718250
                7282936
                31973684
                200cc2d4-ff33-4529-bf6e-d3ceb6caa002
                © 2020
                History

                Comments

                Comment on this article